Financial Performance - The total comprehensive income for the six months ended June 30, 2023, was HKD 46.528 million, a decrease of 34.974 million compared to the previous period[38]. - The company reported a net profit of HKD 46.528 million for the period, compared to a loss of HKD 34.974 million in the previous period[38]. - Revenue for the six months ended June 30, 2023, was HKD 346,382 thousand, representing a 9.7% increase compared to HKD 315,626 thousand in the same period of 2022[50]. - Gross profit for the same period was HKD 167,582 thousand, up 17.6% from HKD 142,554 thousand year-over-year[50]. - Net profit for the period was HKD 68,111 thousand, a significant increase of 56.7% from HKD 43,467 thousand in the previous year[50]. - Adjusted net profit after tax was HKD 70,483 thousand, up 31.7% from HKD 53,537 thousand year-over-year[53]. - The total comprehensive income for the period was HKD 101,501,000, which includes a profit of HKD 67,476,000[65]. - The company reported a profit attributable to owners of HKD 67,476,000 for the six months ended June 30, 2023, compared to HKD 46,528,000 for the same period in 2022, representing a year-over-year increase of 44.8%[179]. - Basic earnings per share increased to HKD 20.325 for the six months ended June 30, 2023, up from HKD 14.029 in the same period of 2022, reflecting a growth of 45%[179]. Revenue and Growth - The total revenue for the first half of 2023 was HKD 261.396 million, representing a growth of 10% year-over-year[38]. - Revenue for the six months ended June 30, 2023, was HKD 346,382,000, an increase of 9.4% compared to HKD 315,626,000 for the same period in 2022[61]. - The revenue from vision correction services was HKD 342,952,000 for the six months ended June 30, 2023, up from HKD 313,086,000 in 2022, marking a growth of 9.5%[126]. - The Chinese segment reported revenue of HKD 72,776,000, significantly increasing from HKD 48,749,000 in the previous year, representing a growth of 49.2%[148]. - The Danish segment saw revenue growth to HKD 42,746,000 from HKD 30,031,000, an increase of 42.4%[148]. - Total revenue from customer prepayments reached HKD 342,250,000 for the six months ended June 30, 2023, compared to HKD 309,649,000 in the same period of 2022, marking an increase of 10.5%[172]. Expenses and Liabilities - The company's total expenses for the six months ended June 30, 2023, amounted to HKD 251,907,000, a rise from HKD 243,198,000 in the same period of 2022, indicating a growth of 3.0%[172]. - The total liabilities increased to HKD 546,729,000 from HKD 497,947,000, indicating a rise in financial obligations[59]. - The company's total liabilities as of June 30, 2023, were HKD 497,947,000, compared to HKD 466,837,000 as of December 31, 2022, indicating an increase in financial obligations[164]. - The company's lease liabilities totaled HKD 399,743,000, with HKD 64,787,000 due within one year[99]. - The company's current lease liabilities rose to HKD 62,813,000 as of June 30, 2023, up from HKD 47,482,000 as of December 31, 2022, marking an increase of approximately 32.3%[198]. Cash Flow and Liquidity - Cash flow from operating activities was HKD 92,282 thousand, down from HKD 108,775 thousand in the same period last year[50]. - Cash and cash equivalents at the end of the period increased to HKD 781,630 thousand from HKD 716,011 thousand at the end of the previous year[50]. - The company maintained a prudent liquidity risk management strategy, ensuring sufficient cash and cash equivalents to provide funding flexibility[74]. - The company's cash flow management included maintaining adequate cash reserves and access to credit facilities[74]. - The cash and cash equivalents as of June 30, 2023, totaled HKD 782,621,000, compared to HKD 779,567,000 as of December 31, 2022, showing a slight increase of 0.3%[188]. Strategic Plans and Investments - The company plans to expand its market presence in Asia, focusing on increasing its clinic network by 20% over the next two years[38]. - The company is investing in new technology for eye care procedures, with an estimated budget of HKD 10 million for R&D in 2023[38]. - The company aims to enhance its service offerings through strategic partnerships and potential acquisitions in the upcoming fiscal year[38]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[60]. - The company plans to continue expanding its market presence, particularly in the UK, Germany, and mainland China, where revenues have shown significant growth[165]. Financial Risks and Management - The company faces various financial risks, including market risk, credit risk, and liquidity risk[93]. - The company’s financial risk management policies remained unchanged since the year-end[71]. - The company reported a foreign exchange risk exposure, where a 5% fluctuation in the RMB against the Euro could impact the after-tax profit by approximately HKD 3,405,000[72]. - The company’s liquidity risk is monitored through rolling forecasts of expected cash flows[97]. - The company’s borrowings as of June 30, 2023, were primarily at fixed interest rates, indicating a low exposure to interest rate risk[94]. Shareholder Information - The company recognized a total of HKD 20,881,000 in dividends declared during the period[65]. - The company proposed an interim dividend of HKD 0.0511 per ordinary share, totaling HKD 17,028,564, to be paid to shareholders[182]. - The company declared a dividend of HKD 0.06266 per share for the year ended December 31, 2022, totaling HKD 20,880,818, down from HKD 33,097,397 for the previous period[160]. Accounting and Compliance - The company has adopted IFRS 17 for insurance contracts without significant changes to its accounting policies[43]. - The company's accounting policies remain consistent with those applied in the annual financial statements for the year ended December 31, 2022[89]. - The company recorded a total tax expense of HKD 24,493,000 for the six months ended June 30, 2023, down from HKD 26,799,000 in the same period of 2022, a decrease of 8.6%[178]. Operational Highlights - The company opened a new clinic in Hong Kong on April 3, 2023, and expects it to commence operations in October 2023[112]. - The company operates in five reportable segments: Germany, Mainland China, Denmark, the UK, and Hong Kong[111]. - The company generated revenue primarily from vision correction services and leasing of ophthalmic equipment and surgical facilities[165]. - Employee salaries increased to HKD 90,814,000 in the first half of 2023, up from HKD 77,381,000 in the same period of 2022, representing a growth of approximately 17.7%[154].

Revenue and Profitability - Total revenue for the six months ended June 30, 2023, was HKD 346.4 million, representing a 9.7% increase compared to HKD 315.6 million in the same period of 2022[11] - Revenue from refractive laser surgery accounted for 34.3% of total revenue, with a year-on-year decline of 13.3% to HKD 116.9 million, primarily due to a decrease in the number of procedures in Germany[6] - The company recorded a gross profit of HKD 167.6 million for the six months ended June 30, 2023, reflecting a gross margin of 48.4%, up from 45.2% in the same period of 2022[11] - Profit for the period increased by 56.7% to HKD 68,111 thousand, compared to HKD 43,467 thousand in the previous year[128] - Adjusted net profit after tax was HKD 70,483 thousand, reflecting a 31.7% increase from HKD 53,537 thousand in 2022[128] - The company reported a profit attributable to owners of HKD 67,476,000 for the six months ended June 30, 2023, compared to HKD 46,528,000 for the same period in 2022, representing a year-over-year increase of 44.8%[138] - The total comprehensive income attributable to owners for the period was HKD 101,501,000, a significant recovery from a loss of HKD 34,974,000 in the previous year[138] Financial Position - The company had cash and cash equivalents of approximately HKD 782.6 million as of June 30, 2023[21] - Total assets as of June 30, 2023, amounted to HKD 1,670,185 thousand, an increase from HKD 1,541,040 thousand at the end of 2022[134] - Total liabilities as of June 30, 2023, were HKD 546,729 thousand, up from HKD 497,947 thousand at the end of 2022[135] - The company's current asset-to-liability ratio is approximately 5.2 times, slightly up from 5.1 times at the end of 2022[40] - The company’s retained earnings increased to HKD 350,810 thousand as of June 30, 2023, up from HKD 304,488 thousand at the start of the year[167] Expenses and Costs - Employee benefit expenses increased by 19.4% to HKD 80.2 million, driven by the transition to full-time contracts for doctors[10] - Sales expenses for the six months ended June 30, 2023, were approximately HKD 34.6 million, an increase of 18.8% compared to the previous year, representing 10% of total revenue[13] - The company incurred a foreign exchange loss related to global offering proceeds of HKD (288,000), contrasting with a gain of HKD 1,496,000 in the previous year[154] - The company’s financial expenses increased to HKD 14,105,000 from HKD 5,507,000, indicating a rise of 156.5%[163] Acquisitions and Expansion - The company completed the acquisition of FreeVis LASIK Zentrum Mannheim GmbH on August 17, 2023, for a total consideration of EUR 8.4 million (approximately HKD 72.5 million), with a maximum consideration of approximately EUR 12.5 million (approximately HKD 107.9 million) subject to adjustments[2] - The acquisition of FreeVis GmbH and PMK is expected to enhance the company's market position in Germany and provide comprehensive ophthalmic services, contributing to a net profit of €1.236 million (approximately HKD 10.2 million) last year, accounting for 12.2% of the company's net profit[45] - The company plans to establish clinics in major cities in China, with an expected allocation of HKD 264.3 million by December 31, 2025[25] - The company continues to seek suitable acquisition targets for private ophthalmic clinics in Europe to expand its network and enhance its market position[48] Corporate Governance and Compliance - The company has adopted a restricted share award plan effective from March 19, 2020, to attract and retain employees[75] - The board has implemented corporate governance measures in line with the corporate governance code[78] - The group reported unaudited consolidated results for the six months ended June 30, 2023, in compliance with the Hong Kong Stock Exchange listing rules[95] - The audit report confirms that the interim financial data complies with the relevant provisions of the Hong Kong Stock Exchange and International Accounting Standard 34[92] Market Outlook and Strategy - The company remains optimistic about its business in Europe, mainland China, and the UK, anticipating improvements in economic data for the remainder of 2023[27] - In the UK, the company expects a 50% increase in surgical capacity in the second half of 2023 due to the addition of two surgeons and a new clinic opening in August[29] - The company anticipates a strong demand for presbyopia treatment in mainland China, with an expected increase in surgical volume in the second half of 2023[46] - The company aims to increase marketing efforts with an expected allocation of HKD 112.3 million by December 31, 2025[25] Shareholder Information - The company declared an interim dividend of HKD 0.0511 per share, totaling approximately HKD 17.03 million, compared to no dividend in the same period last year[51] - As of June 30, 2023, the total number of issued shares of the company is 333,240,000[71] - Susanne Jørgensen holds 181,833,100 shares, representing approximately 54.57% of the total share capital[71] - During the six months ended June 30, 2023, a total of 375,368 shares were granted under the restricted share award plan[76]

Financial Performance - The company reported a significant increase in revenue, achieving a total of $500 million for the fiscal year, representing a 20% growth compared to the previous year[18]. - The group's revenue for the year ended December 31, 2022, was approximately HKD 610.3 million, a decrease of 3.6% compared to HKD 632.9 million in 2021[178]. - The adjusted net profit for the year was HKD 101.2 million, down from HKD 137.3 million in 2021, representing a decline of 26.3%[1]. - The company's net profit for the year ended December 31, 2022, was approximately HKD 83.5 million, a decrease of about 36.9% compared to 2021[138]. - The gross profit was approximately HKD 270.8 million, a decrease of 13.3% from the previous year, with an adjusted gross profit margin of 45.2%[82]. - Adjusted gross profit decreased by approximately 41.8 million HKD (or 13.2%) to about 275.6 million HKD for the year ended December 31, 2022, compared to 317.4 million HKD in 2021[200]. - The adjusted EBITDA for the year was approximately HKD 231.2 million, a decrease of about 14.6% year-on-year, with an adjusted EBITDA margin of 37.9%, down 4.9 percentage points from 2021[113]. Market Expansion and Product Development - The company is expanding its market presence in Asia, targeting a 30% increase in market share by entering three new countries[18]. - New product launches included a state-of-the-art eye surgery device, expected to generate $50 million in sales within the first year[18]. - The company aims to continue executing its expansion plans to meet future demand for ophthalmic surgical treatments in Europe and China[115]. - In 2023, the company plans to open three new clinics in Germany to strengthen its market leadership[115]. - The company is focused on expanding its market presence and enhancing its service offerings in high-end vision correction services across Germany, China, Denmark, and the UK[196]. Acquisitions and Strategic Moves - A strategic acquisition of a local competitor was completed for $100 million, anticipated to enhance operational efficiency and market reach[18]. - The company completed the acquisition of London Vision Clinic Partners Limited for GBP 13.1 million (approximately HKD 138.2 million), with a potential maximum consideration of GBP 34.3 million (approximately HKD 322.6 million)[84]. - The acquisition of London Vision Clinic was completed for a maximum consideration of GBP 34.3 million (approximately HKD 322.6 million), enhancing the group's presence in the high-end refractive surgery market in London[186]. - The company appointed the founder of London Vision Clinic, Professor Dan Reinstein, as an executive director and member of the International Medical Advisory Committee to enhance expertise[130]. Operational Efficiency and Cost Management - The company aims to reduce operational costs by 10% through improved supply chain management and automation[21]. - Employee benefit expenses increased by 29.1% to 140.9 million HKD in 2022, up from 109.2 million HKD in 2021[198]. - The increase in total costs was primarily driven by a rise in surgeries performed at UK clinics, leading to higher employee benefit expenses and depreciation of property, plant, and equipment[198]. - The cost of materials and consumables decreased by 16.9% to 78.3 million HKD in 2022, compared to 94.3 million HKD in 2021, due to reduced surgical volumes and better procurement prices[198]. Risks and Challenges - The company faces risks related to operational failures, including potential claims due to treatment errors or equipment malfunctions[22]. - The ongoing impact of the Russia-Ukraine crisis has negatively affected consumer confidence in Europe, particularly among the younger generation[114]. Employee and Compensation Policies - The company has a fixed contribution rate of 5% of employee-related income for its mandatory provident fund plan in Hong Kong, with a monthly income cap of HKD 30,000[29]. - The board believes that the compensation provided to employees is competitive compared to market standards[44]. - The management team and key employees' continuous service is critical for the company's success, and losing them may incur additional costs for hiring and training replacements[33]. Environmental and Social Responsibility - The company emphasizes environmental principles and will continue to promote sustainable development through various measures[36]. - The company will regularly review its environmental principles and ensure compliance with relevant policies and regulations[36]. - The company is committed to providing the best customer experience for patients and actively seeks customer feedback through a patient survey system[38].

Financial Performance - The company's revenue for the year ended December 31, 2022, was approximately HKD 610.3 million, a decrease of 3.6% compared to HKD 632.9 million in 2021[41]. - The adjusted gross profit margin for 2022 was 45.2%, down from 50.1% in 2021[42]. - The net profit attributable to the company's owners for 2022 was HKD 89.5 million, compared to HKD 133.6 million in 2021, reflecting a decline of approximately 33%[17]. - The group's gross profit for the year ended December 31, 2022, was approximately HKD 270.8 million, a decrease of 13.3% compared to 2021[55]. - The total revenue for the year ended December 31, 2022, was HKD 610,291,000, a decrease of 3.6% compared to HKD 632,931,000 in 2021[121]. - The gross profit for the same period was HKD 270,844,000, reflecting a decline of 13.3% from HKD 312,545,000 in the previous year[121]. - Adjusted net profit after tax was HKD 101,232,000, down 26.3% from HKD 137,278,000 in 2021[121]. - The operating profit for the year ended December 31, 2022, was HKD 132,807 thousand, down from HKD 191,262 thousand in 2021, a decline of around 30.5%[145]. - The total comprehensive income for the year ended December 31, 2022, was HKD 3,286 thousand, significantly lower than HKD 64,726 thousand in 2021, a decrease of about 95.9%[145]. - The company reported a net loss of HKD 701,000 in 2022, compared to a net gain of HKD 1,572,000 in 2021[173]. Revenue Breakdown - Revenue from Germany for the year was approximately HKD 335.6 million, a decrease of about 16.9% compared to 2021, accounting for approximately 55.0% of total revenue[30]. - Revenue from the group's operations in China for the year ended December 31, 2022, was approximately HKD 98.4 million, a decrease of about 33.9% compared to 2021, accounting for approximately 16.1% of total revenue[56]. - Revenue from the group's operations in Denmark for the year ended December 31, 2022, was approximately HKD 65.1 million, a decrease of about 18.5% compared to 2021, accounting for approximately 10.7% of total revenue[57]. - Revenue from ICL implantation procedures was approximately HKD 71.8 million, a decrease of about 19.7% compared to 2021, accounting for approximately 12.0% of total surgical revenue[59]. - The revenue from the German segment for the year ended December 31, 2022, was HKD 407,249 thousand, while the Chinese segment generated HKD 149,012 thousand[156]. Operational Challenges - The company faced operational disruptions in China due to COVID-19, impacting outpatient consultations and surgery bookings[27]. - The company experienced a decline in revenue from crystal replacement surgeries in Germany, China, and Denmark, with decreases of approximately 9.3%, 37.8%, and 18.2% respectively[32]. - The company completed its first surgery at a new clinic in Copenhagen in March 2022 after a delay of approximately 60 days due to COVID-19 restrictions[28]. - The company recorded a significant increase in employee benefit expenses, which rose by 29.1% to HKD 140.9 million in 2022[39]. Future Plans and Expansion - The group plans to open its first clinic in Hong Kong in the second half of 2023, located in Causeway Bay[73]. - The group is constructing three new clinics in Germany, expected to commence operations in the second half of 2023[74]. - The group plans to establish satellite clinics in Beijing and Shanghai, which will enhance the utilization of existing surgical centers and penetrate high-potential cities[84]. - The second clinic in London is nearly completed and is set to begin trial operations in Q2 2023[104]. - The group is actively pursuing acquisition opportunities, particularly targeting renowned private ophthalmology clinics in Europe[75]. Financial Position - As of December 31, 2022, the current ratio was approximately 5.1, down from 6.7 in 2021[88]. - The group had no long-term borrowings as of December 31, 2022, compared to an asset-liability ratio of approximately 0.26% in 2021[89]. - The total assets of the company increased to HKD 1,541,040,000 as of December 31, 2022, compared to HKD 1,369,022,000 in 2021[130]. - Total liabilities rose to HKD 497,947,000, compared to HKD 328,545,000 in the previous year[131]. - The company reported a financial expense of HKD 10,737 thousand for the year ended December 31, 2022, compared to HKD 8,465 thousand in 2021, an increase of approximately 26.8%[145]. Shareholder Information - The company announced a dividend of HKD 0.09932 per share for the year ended December 31, 2021, totaling HKD 33.1 million, which was approved and paid in 2022[26]. - The company proposed a final dividend of HKD 0.06266 per share, totaling approximately HKD 20,880,818, subject to shareholder approval[114]. - The number of shares outstanding at the end of 2022 was 210,598,000, down from 480,411,000 in 2021, indicating a reduction of 56.1%[175].

Financial Performance - Revenue for the six months ended June 30, 2022, was €315,626 thousand, a decrease of 1.3% compared to €319,678 thousand in 2021[10] - Gross profit for the same period was €142,554 thousand, reflecting a decline of 10.8% from €159,825 thousand in 2021[10] - Adjusted gross profit was €144,279 thousand, down 11.7% from €163,367 thousand in the previous year[10] - Profit for the period decreased by 33.7% to €43,467 thousand, compared to €65,578 thousand in 2021[10] - Adjusted net profit after tax was €53,537 thousand, a decrease of 28.2% from €74,575 thousand in the prior year[10] - The company reported an adjusted gross margin of 45.7% for the first half of 2022, compared to 49.1% in the same period of 2021[10] - The adjusted net profit margin after tax was 17.0% for the six months ended June 30, 2022, down from 23.3% in 2021[10] - Total revenue for the six months ended June 30, 2022, was HKD 315,626, a decrease of 1.1% from HKD 319,678 in the same period of 2021[31] - Gross profit for the same period was HKD 142,554, down 10.8% from HKD 159,825 in 2021[31] - Operating profit decreased to HKD 72,770, a decline of 25.0% compared to HKD 96,922 in the previous year[31] - Net profit for the period was HKD 43,467, representing a decrease of 33.7% from HKD 65,578 in 2021[31] - EBITDA for the six months ended June 30, 2022, was HKD 114,584,000, compared to HKD 133,813,000 for the same period in 2021, reflecting a decline of approximately 14.4%[85] - The total expenses for the six months ended June 30, 2022, amounted to HKD 243,198,000, up from HKD 224,187,000 in 2021, which is an increase of 8.5%[111] Market Expansion and Future Outlook - The company is focusing on expanding its market presence and enhancing its service offerings in the eye care sector[10] - Future outlook includes plans for new clinic openings and potential acquisitions to drive growth[10] - The acquisition of London Vision Clinic Partners Limited is expected to contribute to growth targets as outlined in the share purchase agreement[192] Asset and Liability Management - Non-current assets increased to HKD 717,868 as of June 30, 2022, from HKD 412,186 at the end of 2021, representing a growth of 74.0%[26] - Total assets reached HKD 1,533,406, up from HKD 1,369,022 at the end of 2021, indicating an increase of 12.0%[26] - Total liabilities increased to HKD 531,355 as of June 30, 2022, compared to HKD 328,545 at the end of 2021, reflecting a growth of 62.0%[28] - Non-current liabilities rose to HKD 348,522, up from HKD 186,066, marking an increase of 87.2%[28] - Current liabilities totaled HKD 182,833, an increase of 28.4% from HKD 142,479 in the previous year[28] - The company’s total liabilities related to leases increased significantly, with minimum lease payments totaling HKD 332,385 million as of June 30, 2022, compared to HKD 243,990 million as of December 31, 2021, marking a 36.4% increase[162] Cash Flow and Investment Activities - Cash generated from operating activities was HKD 108,775,000, a decrease from HKD 143,592,000 in the previous period, reflecting a decline of approximately 24.3%[42] - The net cash used in investing activities amounted to HKD (118,166,000), significantly higher than HKD (16,567,000) in the prior period, indicating increased investment outflows[42] - The company reported a decrease in cash and cash equivalents of HKD (73,869,000), compared to an increase of HKD 89,882,000 in the previous period[42] - The company acquired a subsidiary for HKD (91,453,000), which contributed to the increase in cash outflows from investing activities[42] Shareholder Returns and Dividends - The company paid dividends totaling HKD (33,097,000) during the period, compared to HKD (9,838,000) in the same period last year, indicating a significant increase in dividend payouts[42] - Basic earnings per share decreased to HKD 14.029 for the six months ended June 30, 2022, down from HKD 19.829 in 2021, reflecting a decline of 29.5%[123] Operational Challenges - The COVID-19 pandemic and related control measures significantly affected operations in major Chinese cities, leading to a temporary suspension of business in Shanghai from late March to early June 2022[191] - Following the easing of strict COVID-19 measures in China, the group's business gradually returned to pre-COVID levels, with outpatient consultation volumes recovering[191] Segment Performance - The German segment generated revenue of HKD 181,794,000, while the Chinese segment contributed HKD 48,749,000, indicating a significant difference in performance across regions[85] - Revenue from vision correction services for the six months ended June 30, 2022, was HKD 313,086,000, a slight decrease of 1.85% from HKD 318,677,000 in the same period of 2021[99] - The Danish segment showed significant growth, with revenue increasing to HKD 54,088,000 in the first half of 2022 from HKD 33,741,000 in the previous year, marking a growth of 60.3%[97]

Financial Performance - Revenue for 2021 reached HKD 632,931,000, representing a 33.6% increase from HKD 473,818,000 in 2020[10] - Gross profit for the year was HKD 312,545,000, with a gross margin of 49.4%, up from 45.2% in the previous year[10] - Net profit for the year was HKD 132,384,000, compared to HKD 64,073,000 in 2020, reflecting a significant growth of 106.5%[10] - Adjusted net profit after tax was HKD 137,278,000, an increase from HKD 70,614,000 in 2020, indicating a growth of 94.4%[10] - Total assets increased to HKD 1,369,022,000 from HKD 1,314,181,000 in 2020, marking a growth of 4.2%[10] - The company’s equity attributable to owners rose to HKD 1,005,552,000, up from HKD 953,292,000 in 2020, a growth of 5.5%[10] - Basic earnings per share for 2021 was HKD 40.673, compared to HKD 19.935 in 2020, representing a 103.7% increase[10] - The adjusted earnings per share was HKD 42.163, up from HKD 21.859 in the previous year, reflecting a growth of 92.7%[10] Revenue Sources - Revenue from crystal replacement surgeries and ICL procedures grew by 39.7%, with prices for both types of surgeries increasing by 8.4%[27] - Revenue from Germany was approximately HKD 404.0 million, accounting for 63.8% of total revenue, and increased by 32.6% year-on-year[33] - Revenue from China was approximately HKD 149.0 million, representing 23.6% of total revenue, with a year-on-year increase of 37.8%[34] Expansion and Acquisitions - The company plans to continue expanding its market presence and invest in new technologies to enhance service offerings[20] - The acquisition of the London Vision Clinic in the UK was completed, enhancing the company's market position in refractive surgery[27] - The company plans to continue its expansion strategy to meet future demand for ophthalmic surgical treatments in Europe and China[28] - The acquisition of London Vision Clinic was completed for £13,130,000 (approximately HKD 138,211,632), with a potential maximum consideration of about £34,327,985 (approximately HKD 361,350,101) depending on adjustments and profit terms[43] - The company is actively pursuing acquisitions, particularly targeting renowned private ophthalmology clinics in Europe to expand its clinic network and enter new regions, focusing on emerging markets[87] Operational Efficiency - Future guidance indicates a focus on increasing operational efficiency and exploring potential acquisitions to drive growth[20] - The gross profit margin improved to 49.4% in 2021 from 45.2% in 2020, attributed to increased surgery volume and enhanced capacity utilization[54] - Adjusted gross profit rose by approximately 48.2% from HKD 214.1 million in 2020 to HKD 317.4 million in 2021, with an adjusted gross profit margin of about 50.1%[59] Employee and Administrative Expenses - Employee benefits accounted for approximately 34.1% of total sales costs in 2021, up from 31.5% in 2020, reflecting the increase in personnel due to business growth[50] - Sales expenses were approximately HKD 53.8 million in 2021, an increase of about 16.8% from the previous year, but the sales expense ratio decreased to 8.5% of total revenue[63] - Total administrative expenses increased by 14.0% to HKD 69,000,000 in 2021, up from HKD 60,491,000 in 2020[66] Future Projections - The company anticipates continued growth, projecting a revenue increase of 25% for the upcoming fiscal year, aiming for €187.5 million[101] - The company is expanding its market presence, with plans to open three new clinics in Germany and one in Denmark by the end of 2022[101] Research and Development - The company has invested €5 million in research and development for innovative ophthalmic solutions[101] - New product development includes the launch of advanced laser technology, expected to enhance surgical outcomes and patient satisfaction[101] Leadership and Governance - The company has a strong leadership team, including Jørn Slot Jørgensen as CEO and Markus Braun as CFO, focusing on overall strategic development and financial management[122] - The company has established a comprehensive compliance and governance framework to support its operational integrity[137] Risks and Challenges - Economic instability may affect the demand for vision correction services, potentially leading to a loss of customers unwilling to pay for premium services[153] - The company's success is significantly dependent on its brand and reputation, with risks associated with treatment errors and service defects[155] Dividend Policy - The company reported a final dividend of HKD 0.09932 per share, totaling approximately HKD 33,097,397, subject to approval at the upcoming annual general meeting[142] - The company has adopted a dividend policy where future annual dividends will not exceed 20% of the distributable net profits attributable to equity shareholders[146]

Revenue and Profit Growth - Revenue for the first half of 2021 reached HKD 319,678,000, a 69.3% increase compared to HKD 188,833,000 in the same period of 2020[10]. - Gross profit for the first half of 2021 was HKD 159,825,000, reflecting a 111.4% increase from HKD 75,620,000 in the first half of 2020[10]. - Adjusted net profit for the first half of 2021 was HKD 74,575,000, a significant increase of 345.5% compared to HKD 16,738,000 in the first half of 2020[10][11]. - The company reported a period profit of HKD 65,578,000, which is a 293.2% increase from HKD 16,679,000 in the same period last year[10]. - Operating profit increased significantly to HKD 96,922,000, compared to HKD 27,567,000 in the previous year, marking a growth of 251.5%[29]. - Net profit for the period was HKD 65,578,000, a substantial rise of 292.5% from HKD 16,679,000 in 2020[31]. - Total comprehensive income for the period was HKD 38,077,000, compared to HKD 15,073,000 in 2020, representing a growth of 152.5%[31]. Financial Position and Assets - The total assets of the company as of June 30, 2021, amounted to HKD 1,366,511,000, an increase from HKD 1,314,181,000 as of December 31, 2020, representing a growth of approximately 4%[24]. - Current assets increased to HKD 952,309,000 from HKD 897,730,000, reflecting a rise of about 6%[24]. - The company's cash and cash equivalents reached HKD 832,715,000, up from HKD 761,894,000, indicating an increase of approximately 9%[24]. - Total equity attributable to the owners of the company rose to HKD 987,552,000 from HKD 953,292,000, marking an increase of around 4%[24]. - Non-current liabilities totaled HKD 204,994,000, compared to HKD 198,032,000, showing a growth of about 3%[26]. - The company reported a decrease in inventory from HKD 36,243,000 to HKD 28,922,000, a decline of approximately 20%[24]. - The retained earnings increased significantly from HKD 124,744,000 to HKD 179,850,000, representing a growth of about 44%[24]. Cash Flow and Liquidity - Operating cash flow for the six months ended June 30, 2021, was HKD 156,909,000, a significant increase from HKD 54,782,000 in the same period of 2020, representing a growth of 186%[37]. - Net cash generated from operating activities reached HKD 143,592,000, compared to HKD 5,313,000 in the prior year, indicating a substantial improvement[37]. - Cash flow from investing activities showed a net outflow of HKD 16,567,000, up from HKD 8,741,000 in the previous year, reflecting increased investment in property, plant, and equipment[37]. - Cash flow from financing activities resulted in a net outflow of HKD 37,143,000, a decrease from HKD 86,970,000 in the same period last year, indicating reduced dividend payments and share repurchases[37]. - The company reported a significant reduction in tax paid, amounting to HKD 13,485,000 for the current period, compared to HKD 51,787,000 in the previous year, reflecting improved cash flow management[37]. Segment Performance - The German segment generated revenue of HKD 202.777 million, the Chinese segment contributed HKD 76.718 million, and the Danish segment added HKD 41.390 million for the six months ended June 30, 2021[70]. - Revenue from Germany for the same period was approximately HKD 201.6 million, an increase of about 55.7% from 2020 and 55.1% from 2019, accounting for approximately 63.1% of total revenue[153]. - Revenue from China reached approximately HKD 76.7 million, up about 110.6% from 2020 and 45.9% from 2019, representing approximately 24.0% of total revenue[155]. - Revenue from Denmark was approximately HKD 41.4 million, an increase of about 80.4% from 2020 and 74.9% from 2019, accounting for approximately 12.9% of total revenue[154]. Expenses and Cost Management - Employee benefits expenses increased to HKD 79,300,000 for the six months ended June 30, 2021, up 53.5% from HKD 51,688,000 in the same period of 2020[8]. - Total expenses rose to HKD 224,187,000, representing a 38.3% increase compared to HKD 161,907,000 for the six months ended June 30, 2020[8]. - The largest component of cost of revenue was employee benefits, accounting for 17.0% of total revenue, down from 18.8% in 2020[169]. - Administrative expenses increased by 42.5% to approximately HKD 37.6 million, mainly due to increased share-based compensation payments[179]. Future Plans and Expansion - The company plans to continue expanding its market presence in China with additional clinic openings in the future[10]. - The company plans to open 10 satellite clinics within two years to enhance the utilization of existing surgical centers[193]. - A new clinic is planned to open in Wiesbaden, Germany, in early 2022, complementing the flagship clinic in Frankfurt[195]. - Construction of a new clinic in Chengdu, China, is underway, expected to open in early 2022[196]. - The company is actively seeking to acquire high-quality refractive surgery clinics in Europe, although expansion has been impacted by the COVID-19 pandemic[197].

Financial Performance - The company's revenue for 2020 was HKD 473.818 million, an increase from HKD 429.692 million in 2019, representing an 10.4% growth[9] - Gross profit for 2020 was HKD 214.1 million, with a gross margin of 45.2%, up from 41.4% in 2019[9] - The net profit for the year was HKD 64.073 million, compared to a loss of HKD 3.686 million in 2019, indicating a significant recovery[9] - Adjusted net profit after tax was HKD 70.614 million, reflecting a 40.3% increase from HKD 50.283 million in 2019[9] - Total assets reached HKD 1,314.181 million, an increase from HKD 1,234.726 million in 2019[9] - The total liabilities decreased to HKD 324.569 million from HKD 383.691 million in 2019, improving the company's financial position[9] - The equity attributable to owners of the company was HKD 953.292 million, up from HKD 807.257 million in 2019[9] - The company reported an adjusted net profit margin of 14.9%, compared to 11.7% in 2019, indicating improved profitability[9] - Basic earnings per share for 2020 were HKD 19.935, a recovery from a loss of HKD 1.341 in 2019[9] Revenue Breakdown - Revenue from Germany was approximately HKD 304.8 million, accounting for about 64.3% of total revenue, with a year-on-year increase of approximately 14.9%[28] - Revenue from China was approximately HKD 108.1 million, accounting for about 22.8% of total revenue, showing a slight decrease of about 4.7% year-on-year due to COVID-19 restrictions[31] - Revenue from lens replacement surgeries was approximately HKD 227.4 million in 2020, up about 13.1% from HKD 201.1 million in 2019, accounting for about 48.0% of total revenue[32] - Revenue from refractive laser surgeries in Germany, Denmark, and China was approximately HKD 133.1 million, HKD 52.3 million, and HKD 42.0 million respectively, reflecting increases of about 13.0%, 21.1%, and 4.9%[32] Operational Expansion - The company plans to continue expanding its market presence and invest in new technologies to enhance service offerings[9] - The Chongqing clinic is set to open in April 2021, marking the seventh clinic in China, aimed at providing quality vision correction services in the southwestern region[24] - The group plans to continue expanding its services and global operations to meet future demand for ophthalmic surgical treatments in Europe and China[24] - The company plans to establish clinics in major Chinese cities, with a specific focus on Chengdu and Chongqing, and has allocated HKD 264.27 million for this purpose, with an expected completion date by December 31, 2025[73] - The new flagship clinic in Copenhagen is expected to be completed in 2021, aimed at meeting the growing demand for services in Denmark[78] Cost Management - Employee benefits accounted for approximately 31.5% of total sales costs, with total sales costs increasing by about 3.1% to approximately HKD 259.7 million[43] - Sales expenses decreased from approximately HKD 60.2 million for the year ended December 31, 2019, to approximately HKD 46.0 million for the year ended December 31, 2020, a reduction of about HKD 14.2 million or 23.5%[55] - Advertising and marketing expenses decreased from approximately HKD 49.0 million in 2019 to approximately HKD 33.1 million in 2020, a decrease of about HKD 15.9 million or 32.5%[55] - Administrative expenses decreased from approximately HKD 88.1 million in 2019 to approximately HKD 60.5 million in 2020, a reduction of about HKD 27.6 million or 31.3%[57] Future Outlook - The company has set a future outlook with a revenue target of €180 million for the next fiscal year, indicating a projected growth of 20%[103] - The company provided an optimistic outlook for the next fiscal year, projecting a revenue growth of 25%[108] - The company plans to enhance its digital marketing strategy, aiming for a 30% increase in online engagement[103] - Future outlook remains positive, with management confident in achieving K% growth in the upcoming quarters[183] Dividend Policy - The company reported a final dividend of HKD 0.02988 per share, totaling approximately HKD 9,837,512, subject to approval at the upcoming annual general meeting[131] - The company has adopted a dividend policy where future dividends will not exceed 20% of the distributable net profits attributable to equity shareholders[134] - The board of directors will review the dividend policy at appropriate times, assessing its effectiveness and making necessary modifications[135] - The company’s overall business conditions, strategies, and future expansion needs are considered before declaring dividends[132] Environmental and Social Responsibility - The company has implemented various environmental protection measures to reduce energy resource consumption, supported by employee engagement[143] - The board has highlighted the commitment to sustainability, with plans to reduce carbon emissions by 30% by 2025[108] - The company emphasizes the importance of maintaining a reliable and high-quality supplier network to ensure service delivery at high safety standards[150] Employee Engagement and Compensation - The company has a competitive compensation structure for employees and provides various promotion opportunities based on performance[148] - The company has established a stock option plan effective until September 23, 2029, aimed at incentivizing and retaining key contributors to its performance and growth[162] - The company believes that the compensation provided to employees is competitive compared to market standards and practices[199] Strategic Acquisitions and Partnerships - A strategic acquisition of a local competitor is anticipated to enhance market share by 10% in the next year[103] - The company completed a strategic acquisition of a local competitor for €50 million, enhancing its service capabilities[108] - Strategic partnerships are being formed to leverage complementary strengths, expected to yield an additional I% in revenue growth[181]

Revenue and Profitability - Revenue for the six months ended June 30, 2020, was HKD 188,833, a decrease of 8.4% compared to HKD 206,175 for the same period in 2019[10]. - Gross profit for the same period was HKD 75,620, down from HKD 89,468, reflecting a decrease of 15.5%[10]. - Adjusted gross profit was HKD 75,620, compared to HKD 92,188 in 2019, representing an 18.0% decline[10]. - Profit for the period increased significantly to HKD 16,679, up 211.2% from HKD 5,359 in the previous year[10]. - Adjusted net profit after tax was HKD 16,738, a decrease of 43.7% from HKD 29,734 in 2019[10][11]. - Operating profit increased to HKD 27,567, up 12.1% from HKD 24,587 in the previous year[35]. - Profit before tax rose to HKD 26,122, an increase of 25.8% compared to HKD 20,874 in 2019[35]. - Net profit for the period was HKD 16,679, significantly higher than HKD 5,359 in the same period last year, representing a 210.5% increase[35]. - Basic and diluted earnings per share for the period were HKD 5.519, compared to HKD 2.177 in the previous year, reflecting a 153.5% increase[37]. - The company reported a total comprehensive income of HKD 15,073 for the period, compared to HKD 2,479 in the same period last year[37]. Financial Position - The company reported total assets of HKD 1,152,731 thousand as of June 30, 2020, a decrease from HKD 1,234,726 thousand as of December 31, 2019, representing a decline of approximately 6.6%[28]. - The total liabilities decreased to HKD 287,964 thousand from HKD 383,691 thousand, indicating a reduction of about 25%[32]. - The equity attributable to owners of the company increased to HKD 822,808 thousand from HKD 807,257 thousand, reflecting a growth of approximately 1.9%[28]. - The company recorded cash and cash equivalents of HKD 697,232 thousand, down from HKD 787,108 thousand, which is a decrease of about 11.4%[28]. - The total current assets amounted to HKD 796,005 thousand, down from HKD 853,731 thousand, indicating a decrease of approximately 6.8%[28]. - The non-current assets totaled HKD 356,726 thousand, a decline from HKD 380,995 thousand, representing a decrease of about 6.4%[28]. - The company reported a liquidity risk management strategy that includes maintaining sufficient cash and cash equivalents, with total assets amounting to HKD 1,152,731,000 as of June 30, 2020[96]. - The total liabilities of the company were HKD 287,964,000, with trade payables at HKD 27,236,000 and borrowings at HKD 2,249,000[78]. - The company’s financial liabilities due within one year amounted to HKD 83,120,000, indicating a manageable short-term debt profile[78]. Operational Performance - The decline in revenue and gross profit is attributed to market conditions and operational challenges faced during the period[10]. - Future strategies may include further market expansion and the opening of additional clinics to enhance revenue streams[10]. - The company opened one new clinic in China during the reporting period, contributing to the adjusted financial metrics[11]. - The company is focused on strategic decision-making based on performance evaluations across its three operational segments: Germany, China, and Denmark[88]. - The group operated a total of 26 clinics and consultation centers globally as of June 30, 2020[192]. Expenses and Cost Management - Employee benefits expenses increased to HKD 51,688,000 for the six months ended June 30, 2020, compared to HKD 46,289,000 in the same period of 2019, representing an increase of 9.7%[116]. - Total revenue costs, selling expenses, and administrative expenses decreased to HKD 161,907,000 for the six months ended June 30, 2020, down from HKD 181,854,000 in 2019, a reduction of 11%[118]. - Sales expenses for the six months ended June 30, 2020, were approximately HKD 22.29 million, a decrease of about HKD 3.28 million or 12.8% compared to the same period in 2019, primarily due to reduced marketing activities caused by the COVID-19 pandemic[197]. - Administrative expenses for the six months ended June 30, 2020, were approximately HKD 26.40 million, a decrease of about HKD 13.17 million or 33.3% compared to the same period in 2019, mainly due to one-time listing expenses recognized in 2019[199]. - Legal and other consulting service fees within administrative expenses were approximately HKD 6.32 million, an increase of about HKD 2.56 million or 68.2% compared to the same period in 2019, due to increased legal and professional fees for compliance and legal advisory services[199]. Impact of COVID-19 - For the six months ended June 30, 2020, the company experienced a decrease in overall revenue due to the COVID-19 pandemic and related operational suspensions[49]. - The company recognized a rental expense reduction of HKD 1,719,000 due to rent concessions received during the pandemic[64]. - Revenue from China decreased significantly to HKD 36,420 from HKD 52,581 year-over-year, reflecting a decline of 30.7%[107]. Shareholder Information - The company did not recommend any interim dividend for the six months ended June 30, 2020, consistent with the same period in 2019[128]. - The company issued 161,661 restricted shares at a fair value of HKD 6.34 per share during the reporting period[148]. - The company’s total issued and paid-up shares remained at 329,234,000 as of June 30, 2020[141].

Financial Performance - Revenue for 2019 reached €48.965 million, an increase of 13.9% compared to €42.961 million in 2018[9] - Gross profit for the year was €20.252 million, representing a gross margin of 41.4%, up from 40.5% in 2018[9] - The company reported a net loss of €420,000 for the year, compared to a profit of €4.291 million in 2018[9] - Adjusted net profit after tax was €5.730 million, slightly up from €5.501 million in 2018, resulting in an adjusted net profit margin of 11.7%[9] - Total assets increased significantly to €141.519 million from €65.943 million in 2018, reflecting a growth of 114%[9] - Total liabilities rose to €43.977 million, compared to €39.268 million in the previous year[9] - Equity attributable to owners of the company increased to €92.467 million from €25.288 million in 2018, marking a growth of 265%[9] - The company’s adjusted earnings per share for the year was €2.121, compared to €2.164 in 2018[9] Revenue Breakdown - Revenue from Germany was approximately €30.2 million, accounting for 61.7% of total revenue, with a growth of 12.5% year-on-year[29] - Revenue from Denmark increased by 45.7% to approximately €5.8 million, driven by more effective marketing strategies[29] - Revenue from China was approximately €12.9 million, a growth of 6.8%, with the company taking immediate action to improve marketing strategies for young myopic patients[30] - Revenue from lens replacement surgeries was approximately €22.9 million, accounting for 46.8% of total revenue, with a 33.3% increase in revenue from trifocal lens surgeries[31] - Revenue from vision correction services was €48,386,000, accounting for 98.8% of total revenue, with a year-on-year increase of 14.2%[34] Operational Strategy - The company plans to expand its market presence and invest in new technologies to enhance service offerings in the coming years[9] - Future guidance indicates a focus on improving operational efficiency and increasing patient volume through strategic marketing initiatives[9] - The company plans to expand its market presence through acquisitions, new clinic constructions, and the introduction of new service lines in 2020[23] - The company aims to enhance its global influence in providing quality ophthalmic services through strategic partnerships[68] - The company is actively developing new technologies, including advanced laser surgery techniques, expected to enhance operational efficiency by 20%[87] Management and Governance - Hennig was appointed as an independent non-executive director on March 25, 2019, and has been with the company since 1983, overseeing overall business operations and strategy[96] - Wright has over 35 years of experience in accounting and finance, having served as a partner at major accounting firms and is responsible for financial oversight[101] - Jørn Slot Jørgensen, the CEO, is the founder of the company and is responsible for overall development strategy and business planning[106] - Markus Braun, the CFO, joined the company in October 2018 and oversees the overall financial and accounting management[106] - The company has established a strong management team with diverse expertise in finance, medical affairs, and strategic development[106] Market Expansion - The company plans to enhance its market presence through new product launches and technological advancements in the ophthalmology sector[120] - The company is exploring potential acquisitions to further expand its footprint in the Asian market[122] - The company aims to increase its market share in Europe by 15% over the next fiscal year through targeted marketing strategies[123] - The company has successfully integrated its subsidiary EuroEyes alz Augenklinik München GmbH, enhancing its operational capabilities in Germany[113] Research and Development - The company is committed to ongoing research and development in refractive laser surgery, with plans to invest 10 million euros in the next two years[120] - The company has established partnerships with leading medical institutions to enhance research and development capabilities, aiming for a 40% increase in innovation output[91] Financial Policies - The company reported a special dividend of €7,400,000, equating to €217.65 per ordinary share, declared on September 23, 2019[134] - The company has adopted a dividend policy where future dividends will not exceed 20% of the group's distributable net profit attributable to equity shareholders[137] - The board will review the dividend policy at appropriate times, assessing its effectiveness and making necessary modifications[138] Risks and Challenges - Economic instability may affect the demand for vision correction services, as customers may become less willing to pay for premium services during downturns[143] - The company’s profitability may be impacted by fluctuations in the prices of lenses, consumables, equipment, and labor costs, which could necessitate adjustments in service pricing[144] - The company faces risks related to the concentration of senior management, which could impact operations if key personnel are lost[140] Employee Engagement - The company provides competitive compensation and various promotion opportunities based on employee performance, viewing employees as one of its most important assets[151] - The company has a patient survey system in place to actively seek customer feedback and improve the customer experience[152] Environmental and Compliance - The company has implemented various environmental protection measures to reduce energy resource consumption, which have received support from employees and have been executed efficiently[146] - The company maintains compliance with all relevant laws and regulations in Germany, Denmark, China, the Cayman Islands, and Hong Kong during the reporting period[149]